Behavioral Phenotyping in Zebrafish: Quantifying Central Nervous System Effects in Preclinical Screening

Neurological disorders affect over 1 in 3 people worldwide, according to the World Health Organization. Their combined burden (disability, illness, and premature mortality) has increased by about 18% in the last 35 years, and they now represent the leading cause of illness and disability globally.

Since 2013, we have been one step closer to tackling this problem. That year, the sequenced genome of the zebrafish was published. It revealed that 70 % of human genes have at least one ortholog in zebrafish, and more than 80 % of genes associated with diseases are conserved. Combined with optical transparency, ease of manipulation, and cost-effectiveness, these features position zebrafish as a key model for combating one of the greatest battles of the 20^th century: neurological diseases.

What Is Behavioral Phenotyping and Why Does It Matter in CNS Drug Discovery?

Many neurological, neurodegenerative, and psychiatric conditions first surface as altered patterns of movement, learning, anxiety-like responses, or social behavior in animal models. Behavioral phenotyping means measuring these actions and turning them into data. We quantify locomotion, learning and memory, social interaction, and sensorimotor responses to obtain functional endpoints in vivo that complement molecular and histological analyses.

Measuring those outputs directly in a vertebrate organism, like zebrafish,links mechanism to function,helping evaluate disease processes and pharmacology. Zebrafish share all core neurotransmission systems with mammals, including dopaminergic, serotonergic, glutamatergic, and GABAergic pathways, but also neuronal pathways and brain structures. Because of this conservation, changes in behavior can be reported on the functional state of drug targets and neural circuits that matter across species.Automated tracking and high-content platforms now make these measurements precise, reproducible, and scalable (Figure 1). But the interpretation of behavioral testing still requires contextualization. Zebrafish are a great asset to guide researchers, but just like any other model, they cannot recapitulate all aspects of human behavior. They serve to streamline the drug development pipeline before moving to costly rodent models, reducing the number of mammals used.

Figure 1. Videotracking of larval zebrafish locomotion using the DanioVision (Noldus IT) software. It is a complete system designed for the analysis of larval activity, movement patterns, and response to external stimuli. 

Zebrafish as a Model for High-Throughput CNS Phenotyping

Most foundational behaviors are early established in the zebrafish central nervous system (CNS) developmental timeline. From 5 to 7 days post-fertilization (dpf), larvae show spontaneous swimming, startle reflexes, phototaxis, and thigmotaxis that can be captured reliably in multi-well plates in a high-throughput format. As task complexity increases, testing moves to later development stages to support memory, social interaction, and associative learning. Early effects are measured in larvae, while models that require a higher degree of neural development are performed in adult zebrafish. 

The interpretability of these readouts is strengthened by conserved neurochemical signaling. If a compound alters activity, we can attribute that shift to specific pathways, providing a cleaner mechanistic link to the intended target. 

Quantifying Behavioral Endpoints: Anxiety, Seizures, Hyperactivity and More

Changes in movement, anxiety-like responses, learning, or social behavior are early, sensitive indicators of therapeutic effect, as many neuroactive compounds act by tuning neural activity, transmission, or plasticity. On the other hand, these changes could also indicate a neurotoxic effect when evaluating potential drug candidates. Zebrafish assays combine early-emerging, stereotyped behaviors with automated tracking. This allows high-throughput, reproducible CNS phenotyping across development. A great behavioral phenotyping example is the light-dark preference test, which quantifies baseline movement and the activity change caused by rapid light shifts. Typical variables are distance moved, velocity, and the magnitude of activity shifts at light-to-dark or dark-to-light switches (Figure 2). This assay offers a simple readout of basal locomotion and arousal state that is scalable for testing the neurotoxic effects of multiple compounds.

Figure 2. General motor activity evaluation. Light/Dark locomotion pattern of zebrafish larvae in response to a negative control, a neurotoxic agent (positive control), and a study compound that does not produce neurotoxic effects on basal locomotor activity.

Complementary assays target exploration and anxiety-like behavior. The novel tank diving test measures vertical exploration dynamics, while the open field test quantifies locomotion and thigmotaxis. Cognitive domains leverage the T/Y-maze for spatial learning and working memory, novel object recognition for recognition memory, and conditioned place preference for associative learning and reward sensitivity. Sensorimotor gating is assessed with prepulse inhibition, and social function is captured via shoaling and conspecific preference. Each test aligns with specific developmental windows and can be used to interrogate potential drug candidates for diverse CNS diseases, as summarized in Table 1. 

Table 1. Zebrafish behavioral assays by functional domain and CNS disease relevance. Adapted from: Pansera L. et al. Zebrafish as an Integrative Model for Central Nervous System Research: Current Advances and Translational Perspectives. Life (Basel). 2025 Nov 14;15(11):1751.

Activity level and seizure risk are straightforward to measure as combined endpoints. Using larval tracking, such as DanioVision, we can detect hyper- or hypoactivity after drug exposure. Across domains, the availability of automated tracking and high-content platforms improves precision and reproducibility, facilitating the detection of subtle, dose-dependent effects from neurotoxic insults, genetic mutations, or drug treatments. It turns behavior into arobust endpoint for early efficacy signals.

From Phenotypic Screening to Translational Biomarkers: Strategic Applications

In preclinical screening, behavior provides an immediate, functional readout of CNS activity. When neuroactive substances modulate neuronal firing, neurotransmission, or synaptic plasticity, consequent changes in locomotion, anxiety-like behavior, learning capacity, or social interaction often appear early and can be measured with high temporal resolution. This makes zebrafish phenotyping screening useful forranking hits, optimizing doses, and flagging potential side effects before moving into more resource-intensive mammalian studies.

When zebrafish behavioral data are interpreted within their evolutionary and neuroanatomical framework and paired with complementary mammalian readouts, they guide researchers toward conserved mechanisms and the most informative features of a phenotype. Under this complementary strategy, zebrafish behavioral phenotyping becomes a practical path to translational biomarkers: it narrows candidate mechanisms, clarifies pharmacodynamic windows, and helps determine which endpoints are worth carrying forward into downstream models. 

Source

Pansera L, Mhalhel K, Cavallaro M, Aragona M, Laurà R, Levanti M, Guerrera MC, Abbate F, Germanà A, Montalbano G. Zebrafish as an Integrative Model for Central Nervous System Research: Current Advances and Translational Perspectives. Life (Basel). 2025 Nov 14;15(11):1751. doi: 10.3390/life15111751.

World Health Organization. Over 1 in 3 people affected by neurological conditions, the leading cause of illness and disability worldwide [Internet]. Geneva: World Health Organization; 2024 Mar 14 [cited 2025 Dec 22]. Available from: https://www.who.int/news/item/14-03-2024-over-1-in-3-people-affected-by-neurological-conditions--the-leading-cause-of-illness-and-disability-worldwide

By Miriam Martínez

Miriam is a Human Biologist with a strong background in neuropharmacology and a passion for bridging science and innovation. After earning a master’s degree in the Pharmaceutical and Biotech Industry, she completed her PhD in Biomedicine at Pompeu Fabra University (Barcelona), where her research focused on the behavioral analysis of animal models for neurophenotypical characterization. Following her doctoral studies, Miriam transitioned into the healthcare marketing and communication sector, where she played a key role in developing impactful marketing strategies and educational campaigns for leading pharmaceutical brands. She now leverages her scientific expertise, strategic thinking, and creative communication skills in her current role at ZeClinics.